ÌÇÐÄvlog

[Skip to Navigation]
Sign In

October 2024 - July 1959

Decade

Year

Issue

November 2014, Vol 71, No. 11, Pages 1343-1457

In This Issue of JAMA Neurology

Highlights

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1343. doi:10.1001/jamaneurol.2013.4176
Viewpoint

The Future of Research in Parkinson Disease

Abstract Full Text
JAMA Neurol. 2014;71(11):1351-1352. doi:10.1001/jamaneurol.2014.1717

This Viewpoint highlights aspects of future research aimed at addressing critical questions about Parkinson disease.

Editorial

Statin Use and Brain Hemorrhage: Real Risk or Unfounded Fear?

Abstract Full Text
JAMA Neurol. 2014;71(11):1353-1354. doi:10.1001/jamaneurol.2014.2463

Mycophenolate Mofetil to Treat Neuromyelitis Optica: Is It Time for a Randomized Trial?

Abstract Full Text
JAMA Neurol. 2014;71(11):1354-1357. doi:10.1001/jamaneurol.2014.2359

Preclinical Biomarkers in Alzheimer Disease: A Sum Greater Than the Parts

Abstract Full Text
JAMA Neurol. 2014;71(11):1357-1358. doi:10.1001/jamaneurol.2014.2462
Original Investigation

Effect of Statin Use During Hospitalization for Intracerebral Hemorrhage on Mortality and Discharge Disposition

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1364-1371. doi:10.1001/jamaneurol.2014.2124

This retrospective cohort study reports that statin use is strongly associated with improved outcomes after intracerebral hemorrhage and that the cessation of statin use is strongly associated with worsened outcomes after intracerebral hemorrhage.

Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1372-1378. doi:10.1001/jamaneurol.2014.2057

Huh et al evaluate the efficacy and safety of mycophenolate mofetil treatment in patients with neuromyelitis optica spectrum disorder. See also the Editorial by Cree.

Synergistic Effect of β-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1379-1385. doi:10.1001/jamaneurol.2014.2031

Mormino et al determine whether neuroimaging markers of β-amyloid and neurodegeneration are independently or synergistically associated with longitudinal cognitive decline in 166 clinically normal individuals. Based on imaging markers, clinical normal individuals were categorized into preclinical Alzheimer disease stages. See the Editorial by Resnick.

The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1386-1393. doi:10.1001/jamaneurol.2014.1895

Cohen et al evaluate the relationship between Timed 25-Foot Walk (T25-FW) speed and the Physical Component Summary score to understand the clinical meaning of T25-FW walking speed in multiple sclerosis.

Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease: A Genome-Wide Association Study

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1394-1404. doi:10.1001/jamaneurol.2014.1491

Naj et al investigate the effects of known AD risk loci in modifying age at onset (AAO) and estimate their cumulative effect on AAO variation using data from genome-wide association studies in the Alzheimer Disease Genetics Consortium. Age at disease onset was abstracted from medical records among participants with late-onset AD diagnosed per standard criteria.

APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1405-1412. doi:10.1001/jamaneurol.2014.1455

Mata et al determine whether common variation in the APOE, MAPT, and SNCA genes is associated with cognitive performance in patients with Parkinson disease.

Expanding the Phenotype Associated With the NEFL Mutation: Neuromuscular Disease in a Family With Overlapping Myopathic and Neurogenic Findings

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1413-1420. doi:10.1001/jamaneurol.2014.1432

Agrawal et al elucidate the molecular cause of a neuromuscular disease among a family in which 4 members, a mother and her 3 sons, were affected. Two manifested nemaline myopathy, while the other 2 had a nonspecific myopathy. Whole-genome sequencing and linkage analysis identified a variant in NEFL that explains the phenotype.

The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1421-1428. doi:10.1001/jamaneurol.2014.1472

This study determined whether glatiramer acetate therapy normalizes dysregulated B-cell proliferation and cytokine production in patients with MS.

Case Report/Case Series

Opportunistic Infections of the Retina in Patients With Aquaporin-4 Antibody Disease

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1429-1432. doi:10.1001/jamaneurol.2014.1620

George et al describe 2 patients with aquaporin-4 antibodies who experienced vision loss resulting from opportunistic infections during immunosuppressive therapy.

Seroprevalence of Aquaporin-4–IgG in a Northern California Population Representative Cohort of Multiple Sclerosis

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1433-1436. doi:10.1001/jamaneurol.2014.1581

Pittock and colleagues tested aquaporin 4-IgG in a predominantly white non-Hispanic population representative cohort of 3293 potential patients with multiple sclerosis to address what the rate of aquaporin 4-IgG is in multiple sclerosis and how frequently neuromyelitis optica spectrum disorders are misdiagnosed as multiple sclerosis.

Review

Emerging Therapies for Glioblastoma

Abstract Full Text
JAMA Neurol. 2014;71(11):1437-1444. doi:10.1001/jamaneurol.2014.1701

Thomas et al review the characterization and evolving treatments of glioblastoma.

Clinical Pathologic Conference

A Case of Early-Onset Rapidly Progressive Dementia

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1445-1449. doi:10.1001/jamaneurol.2014.836

This Clinical Pathologic Conference discusses the clinical approach, differential diagnosis, and neuropathologic findings in a 62-year-old man with rapidly progressive cognitive decline.

Images in Neurology

Ping-Pong Gaze: Sherrington Would Not Have Done It Better

Abstract Full Text
has multimedia
JAMA Neurol. 2014;71(11):1450. doi:10.1001/jamaneurol.2014.1072
Research Letter

Imaging Blood-Brain Barrier Dysfunction in Football Players

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1453-1455. doi:10.1001/jamaneurol.2014.2682
Comment & Response

The Central Clock in Patients With Parkinson Disease

Abstract Full Text
JAMA Neurol. 2014;71(11):1455-1456. doi:10.1001/jamaneurol.2014.2708

The Central Clock in Patients With Parkinson Disease—Reply

Abstract Full Text
JAMA Neurol. 2014;71(11):1456. doi:10.1001/jamaneurol.2014.2711
Correction

Error in Byline

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1457. doi:10.1001/jamaneurol.2014.3651

Error in Byline

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1457. doi:10.1001/jamaneurol.2014.3675
Book and Media Review

Review of Rehabilitation in Movement Disorders

Abstract Full Text
JAMA Neurol. 2014;71(11):1451-1452. doi:10.1001/jamaneurol.2014.2052
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2014;71(11):1345. doi:10.1001/jamaneurol.2013.4177
×